Neuphoria's Social Anxiety Treatment Fails Phase 3 Trial
Neuphoria's AFFIRM-1 Phase 3 trial for BNC210 social anxiety treatment misses all endpoints. Company halts SAD program, reviews options.
Already have an account? Sign in.